PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9559247

Benign prostatic hyperplasia.

L Kuritzky
View original source ↗Export metadata ↓

Abstract

Insight into the dysfunctional physiology of benign prostatic hyperplasia has expanded appropriate therapies. As the proportion of the population to whom BPH will be a problem increases our attention is directed to evolution in clinical management.

Explore related subjects

Adrenergic alpha-AntagonistsHumansMaleProstatic HyperplasiaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Kuritzky. 1998. Benign prostatic hyperplasia.. https://pubmed.ncbi.nlm.nih.gov/9559247/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 3. Approaches to eliminate opioid agonist metabolites by using substituted phenylpiperazine side chains.

Dihydropyrimidinones, such as 1, represent a novel class of alpha(1a) adrenoceptor antagonists with potential for the treatment of benign prostatic hyperplasia (BPH) (see part 1 of this series). Analysis of the metabolites of 1 revealed that 4-methoxycarbonyl-4-phenylpiperidine is formed as the major metabolite and is an agonist at the mu-opioid receptor. To circumvent any potential liability resulting from the metabolite, we decided to identify alternate templates devoid of agonist activity at the mu-opioid receptor to replace the 4-methoxycarbonyl-4-phenylpiperidine moiety. The present study describes the synthesis and SAR of dihydropyrimidinones linked to substituted 4-phenylpiperazine containing side chains. Compound (+)-38 was identified as a lead compound with a binding and functional profile comparable to that of 1. The putative metabolite 2-carboxamidophenylpiperazine has negligible affinity for the mu-opioid receptor.

Adrenergic alpha-Antagonists↗
PubMed1999

Subthalamic influences on the cardiorespiratory functions in the cat.

The electrical stimulation of the subthalamic nucleus (STN) caused a conspicuous increase in arterial blood pressure (BP), heart rate (HR) and respiratory rate (RR) in freely moving cats. The pulse pressure (PP) increased significantly following an initial decrease at the beginning of the 10 s long stimulation. A rebound bradycardia occurred after switching off the stimulation. Cardiorespiratory responses might be elicited also during ketamine-induced anaesthesia. The BP responses reduced highly under the blockade of the alpha(1)-adrenergic receptors. The neurotoxic lesions of the ipsilateral globus pallidus caused no significant alterations in the cardiorespiratory responses to STN stimulation. It is concluded that, besides its role in the motor control, STN is also involved in adjusting the cardiorespiratory functions to the somatomotor activity.

Adrenergic alpha-Antagonists↗